Preretinal neovascularization after bevacizumab injections in a patient with von Hippel-Lindau syndrome.
Randy A
RA
Walker
Kevin M
KM
Colleaux
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D018324:Hemangioma, Capillary / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000209:etiology; D015861:Retinal Neovascularization / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body; D006623:von Hippel-Lindau Disease / Q000150:complications*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab